Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
DiaMedica Therapeutics Inc
DMAC
Healthcare
Biotechnology
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute...
ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:DMAC)
New Post
View:
Posts & Comments
Threaded Posts
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 7:46am
DiaMedica Therapeutics Inc. (DMAC): Navigating the Challenge
https://beyondspx.com/2024/08/02/diamedica-therapeutics-inc-dmac-navigating-the-challenges-of-advancing-a-promising-stroke-treatment/
(17)
•••
StockscoutX
X
Post by
StockscoutX
on Feb 03, 2021 11:31am
Here is something to think about to diversify.
Aristotle - 10 Cancers - One Sample of Blood Unlimited Possibilities. It's on the Toronto Stock Exchange in Canada. QR is about to be released soon as the deployment of Aristotle. The ticker
...more
(0)
•••
TradeSaver2
X
Post by
TradeSaver2
on Nov 10, 2020 1:43pm
C'mon Jinxmom
you spinless loser...enjoy your cr@p life...end it....we are having fun!
(17)
•••
StockscoutX
X
Post by
StockscoutX
on Sep 15, 2020 7:06pm
DiaMedica Therapeutics to Present at Conference
DiaMedica Therapeutics to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020 Link
(17)
•••
StockscoutX
X
Post by
StockscoutX
on Sep 15, 2020 7:03pm
DiaMedica Announces First Patients Dosed
DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study Link
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.